LifeArc CEO: UK Charity Is Cashing In Its Keytruda ‘Jackpot’ To Expand R&D Focus

The CEO of LifeArc tells Scrip why the UK-based medical research charity has decided to monetize a part of its royalty interest in Merck’s hugely successful cancer drug, Keytruda.

Gambling
LifeArc hit the jackpot co-developing Merck & Co's PD-1 inhibitor Keytruda • Source: Shutterstock

The UK charity LifeArc has decided to sell a portion of its royalty interest in Keytruda (pembrolizumab), the hugely successful anti-PD-1 cancer therapy it co-developed with Merck & Co. Inc. It will use the funds to expand its capacity as a translational ‘bridge’ between research-oriented academia and the wider pharma industry, the UK charity’s CEO told Scrip.

Melanie Lee was speaking after LifeArc announced on 20 May that it had received just under $1.3bn from CPPIB Credit...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.